A few notes from the weekend that was. We hope you had a good one. Several of your resident bloggers will be converging on New York this week for our Pharmaceutical Strategic Alliances conference (remember, UBS isn't the only game in town this week!). Hope to see some of you there. Stay tuned to IN VIVO Blog for a few updates from the conference on Wednesday and Thursday.- Profit up but care down at many PE-backed nursing homes, says the New York Times in a Sunday feature.
- Pfizer gets maraviroc approval in the EU--here's the early morning release--and Novartis gets an EU OK for its transdermal Exelon mild-to-moderately-severe Alzheimer's disease patch. Both approvals were expected.
- The WSJ is the latest paper to take a gander at GSK's slightly unusual CEO succession contest, while the FT wonders who will replace Jon Symonds as CFO at AZ (hat tip, Pharmagossip).
No comments:
Post a Comment